51�ԹϺ���

The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a 51�ԹϺ��� researcher says that 2024 is a “learning year” for Alzheimer’s drug development.

The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a 51�ԹϺ��� researcher says that 2024 is a "learning year" for Alzheimer's drug development.

The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a 51�ԹϺ��� researcher says that 2024 is a “learning year” for Alzheimer’s drug development.

Researchers identified sildenafil, known commercially as Viagra, as a promising candidate for treating Alzheimer’s disease. Leveraging artificial intelligence the team analyzed vast amounts of data, including insurance claims and brain cell observations, to highlight sildenafil’s potential benefits in reducing Alzheimer’s prevalence and neurotoxic proteins.

Most ARIA cases are mild, but some have been fatal

Recently approved disease-modifying treatments for Alzheimer's disease have created a sudden demand, but these and other drugs in the pipeline are not for all patients with clinical Alzheimer's symptoms, experts said.

Looking ahead to 2024 and beyond: "There is so much more to be done"

Over the past year, the field has experienced another significant leap of growth, powered by advances in translational research and capped off by the approval of lecanemab (Leqembi; Eisai), the first traditionally approved therapy in nearly two decades.